reference/18302102

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18302102

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
issn	1756-8722
issueIdentifier	1
pageRange	47-
publicationName	Journal of Hematology & Oncology
startingPage	47
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d9f13d1c825970bf1acfa3e330f78b75
bibliographicCitation	Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Yan P, Zou J. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Journal of Hematology & Oncology. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77c72e1d8553594bf5b0f685d1a947ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_22616e94cc23bf2703b118f9a99d7252 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab3085b763887a35907bad4ca3a9f1e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bced3033bbc0b3c3c609ee9cbb54989 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5085-6761 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e963f44ca67ea78601671a95e686de1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbf60ecf6c3dde1cb62b2f58c3e39651 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_edb111f5c21e55a38254c6477df048ab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc8053e8cc6666ff7702f34ac4a21358 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7160-9241 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ab80c85e05ca9b49bad1efc4a130f80 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fbb3aad70baec7bacf12573951be1bba http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c14e669ce16e0b3dcd989fc84b37a30 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d4addc75c0e32ac18dc6e0aca595e33 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8c3850cd66f9ba584eab559d9618bde http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_18fc094c9db09c5a8183176097560116 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5cb80f4faee87301bb435e25707e766a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76cc40a32669b56e91d62b4716c5cc49 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2dd0c76ba61c89c8368d11a98d665a90
date	2020-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC7216554 https://pubmed.ncbi.nlm.nih.gov/32393323 https://doi.org/10.1186/s13045-020-00886-2
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/34231 https://portal.issn.org/resource/ISSN/1756-8722
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
discusses	http://id.nlm.nih.gov/mesh/M000675754 http://id.nlm.nih.gov/mesh/M000651317 http://id.nlm.nih.gov/mesh/M0556300
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID108157 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8094 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8662

Total number of triples: 47.